SCHEMBL4980646

SCHEMBL4980646

Cc1csc2c(=O)n(-c3ccc(F)cc3)c(CC(C)C(F)(F)F)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TGM2 P21980 1/20 0.36
GRM1 Q13255 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.34
TSHR P16473 2/20 0.33
HTT P42858 1/20 0.33
HKDC1 Q2TB90 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE7A Q13946 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 1/20 0.32
MAPK1 P28482 1/20 0.32
POLB P06746 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
GRM5 P41594 1/20 0.32
PDE10A Q9Y233 1/20 0.31
MDM2 Q00987 1/20 0.31
PDE5A O76074 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4296174 0.88 POLB (0.42) KDM4EGRM1MAPK1POLBGRM5
SCHEMBL4978987 0.72 SMN1; SMN2 (0.37) SMN1; SMN2TSHRHKDC1PDE4BMEN1
SCHEMBL4516570 0.72 POLB (0.41) NPSR1GRM1SMN1; SMN2TSHRHTT
SCHEMBL3178920 0.71 KDM4E (0.36) KDM4ENPSR1TGM2GRM1SMN1; SMN2
SCHEMBL4523280 0.71 POLB (0.40) KDM4ENPSR1GRM1SMN1; SMN2TSHR
SCHEMBL3178928 0.71 KDM4E (0.36) KDM4ENPSR1TGM2GRM1SMN1; SMN2
SCHEMBL14292701 0.70 ALDH1A1 (0.36) KDM4ENPSR1SMN1; SMN2TSHRHKDC1
SCHEMBL11908071 0.70 GRM1 (0.40) KDM4ENPSR1TGM2GRM1SMN1; SMN2
SCHEMBL2237018 0.70 GRM1 (0.40) KDM4ENPSR1TGM2GRM1SMN1; SMN2
SCHEMBL4083548 0.70 GRM1 (0.43) KDM4ENPSR1TGM2GRM1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US claimed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
WO-2008024433-A2 HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives PIGS, GPR174, GPR17 KDM4E 3957/4885NPSR1 118/4885TGM2 2636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.